Industry Symposium Supported by Sanofi: Beyond a one-size-fits-all approach: Personalizing therapy in newly diagnosed multiple myeloma

Chair(s)

• 

  Thomas Martin, MD

  Clinical Professor of Medicine
  Department of Hematology, University of California at San Francisco, San Francisco, CA, USA
  San Francisco, United States

Presentations:

• 8:00 AM – 8:05 AM East Coast USA Time

  Introduction
  

  Speaker: Thomas Martin, MD – Department of Hematology, University of California at San Francisco, San Francisco, CA, USA
• 8:05 AM – 8:20 AM East Coast USA Time

  Tailored to fit: New approaches in transplant-ineligible NDMM
  

  Speaker: Xavier P. Leleu, MD, PhD (he/him/his) – Hospital La Mileterie, Poitiers, France
• 8:20 AM – 8:35 AM East Coast USA Time

  Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
  

  Speaker: Elias K. Mai (he/him/his) – Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
• 8:35 AM – 8:55 AM East Coast USA Time

  What is the best fit? Anti-CD38-VRd quads or anti-CD38-KRd quads as a new standard of care in NDMM
  

  Speaker: Thomas Martin, MD – Department of Hematology, University of California at San Francisco, San Francisco, CA, USA

  Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Dana-Farber Cancer Institute, Boston, MA, USA
• 8:55 AM – 9:00 AM East Coast USA Time

  Q&A
  

  Panelist: Thomas Martin, MD – Department of Hematology, University of California at San Francisco, San Francisco, CA, USA

  Panelist: Xavier P. Leleu, MD, PhD (he/him/his) – Hospital La Mileterie, Poitiers, France

  Panelist: Elias K. Mai (he/him/his) – Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

  Panelist: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Dana-Farber Cancer Institute, Boston, MA, USA